UC Davis Health: Department of Surgery, 4625 2nd Ave., Research II, Room 3101, Sacramento, CA, 95817, USA.
Adv Biol (Weinh). 2022 Feb;6(2):e2101099. doi: 10.1002/adbi.202101099. Epub 2022 Jan 13.
Multiple sclerosis (MS) is a debilitating degenerative disease characterized by an immunological attack on the myelin sheath leading to demyelination and axon degeneration. Mesenchymal stem/stromal cells (MSCs) and secreted extracellular vesicles (EVs) have become attractive targets as therapies to treat neurodegenerative diseases such as MS due to their potent immunomodulatory and regenerative properties. The placenta is a unique source of MSCs (PMSCs), demonstrates "fetomaternal" tolerance during pregnancy, and serves as a novel source of MSCs for the treatment of neurodegenerative diseases. PMSCs and PMSC-EVs have been shown to promote remyelination in animal models of MS, however, the molecular mechanisms by which modulation of autoimmunity and promotion of myelination occurs have not been well elucidated. The current review will address the molecular mechanisms by which PMSC-EVs can promote remyelination in MS.
多发性硬化症(MS)是一种使人衰弱的退行性疾病,其特征是免疫系统对髓鞘进行攻击,导致脱髓鞘和轴突变性。间充质干细胞(MSCs)和分泌的细胞外囊泡(EVs)因其强大的免疫调节和再生特性,已成为治疗多发性硬化症等神经退行性疾病的有吸引力的治疗靶点。胎盘是间充质干细胞(PMSCs)的独特来源,在怀孕期间表现出“胎母”耐受,并且是用于治疗神经退行性疾病的新型间充质干细胞来源。已经证明 PMSCs 和 PMSC-EVs 可促进 MS 动物模型中的髓鞘再生,但是,调节自身免疫和促进髓鞘形成的分子机制尚不清楚。目前的综述将讨论 PMSC-EVs 促进 MS 髓鞘再生的分子机制。